Your browser doesn't support javascript.
loading
Recent Advances in the Treatment of Opioid Use Disorder.
Kuppalli, Sumanth; Seth, Raghav; Orhurhu, Vwaire; Urits, Ivan; Kaye, Alan D; Hunter, Corey; Gulati, Amitabh; Adekoya, Peju; Kaye, Adam M; Jones, Mark R.
Affiliation
  • Kuppalli S; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Seth R; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Orhurhu V; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Urits I; Southcoast Health, Southcoast Health Physicians Group, Fall River, MA, USA.
  • Kaye AD; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
  • Hunter C; Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
  • Gulati A; Ainsworth Institute of Pain Management, New York, NY, USA.
  • Adekoya P; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kaye AM; Departments of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Jones MR; Thomas J. Long School of Pharmacy and Health Sciences, Department of Pharmacy Practice, University of the Pacific, Stockton, CA, USA.
Curr Pain Headache Rep ; 25(4): 23, 2021 Mar 11.
Article in En | MEDLINE | ID: mdl-33693999
ABSTRACT
PURPOSE OF REVIEW Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States' healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy. RECENT

FINDINGS:

Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR), but several pharmacologic, clinical, and practical barriers limit these treatments' market viability. This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Analgesics, Opioid / Narcotic Antagonists / Opioid-Related Disorders Limits: Humans Language: En Journal: Curr Pain Headache Rep Journal subject: FISIOLOGIA / NEUROLOGIA / PSICOFISIOLOGIA Year: 2021 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Analgesics, Opioid / Narcotic Antagonists / Opioid-Related Disorders Limits: Humans Language: En Journal: Curr Pain Headache Rep Journal subject: FISIOLOGIA / NEUROLOGIA / PSICOFISIOLOGIA Year: 2021 Document type: Article Affiliation country: